MELBOURNE, Australia, March 13 /PRNewswire-FirstCall/ -- Phosphagenics Limited (“Phosphagenics”) (AIM: PSG) announced today that Dr Esra Ogru, Executive Vice President, and Mr Harry Rosen, Chief Executive Officer, will present at the Cowen and Company 27th Annual Health Care Conference March 12-15, 2007.
Cowen and Company, LLC is one of North America’s leading investment banks, specializing in the healthcare sector. The presentation is scheduled in the US for 11:00 a.m. EDT on Thursday, March 15, 2007. The event will be held in Boston, MA, at The Boston Marriott Copley Place Hotel. An audio webcast of the presentation will be available on Phosphagenics’ website: http://www.phosphagenics.com/main/Investors_presentations.htm
About Phosphagenics Limited
Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.
Phosphagenics’ core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.
Phosphagenics’ shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange’s Alternative Investment Market (PSG). An ADR - Level 1 program has been established in the US with the Bank of New York (PPGNY) for US investors to trade in Phosphagenics’ stock on the ‘over-the- counter’ market.
About Cowen Group, Inc.
Cowen Group, Inc., through Cowen and Company, LLC and Cowen International Limited, provides investment banking services, including underwriting and other capital raising solutions, equity research, sales, trading and mergers and acquisitions advice, to emerging growth companies in sectors including healthcare, technology, alternative energy, media and telecommunications and consumer.
For more information, please visit Phosphagenics’ web site at http://www.phosphagenics.com
Phosphagenics
CONTACT: Dr Esra Ogru, Executive Vice President, or Mr Harry Rosen, ChiefExecutive Officer, both of Phosphagenics Ltd, +61-3-9605-5900; or USInvestor and Media Contacts: Mr Evan Smith, CFA, +1-212-850-5606, or MrJohn Capodanno, +1-212-850-5705, both of Financial Dynamics
Web site: http://www.phosphagenics.com/
